INDICATIONS AND USAGE
Erloxha is a kinase inhibitor indicated for:
Maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
Treatment of locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.
DOSAGE AND ADMINISTRATION
The dose for NSCLC is 150 mg/day.
The dose for pancreatic cancer is 100 mg/day.
All doses of Erloxha should be taken on an empty stomach at least one hour before or two hours after food.
DOSAGE FORMS AND STRENGTHS
Film-coated tablets: 150 mg.
STORAGE OF ERLOXHA
Store ERLOXHA at room temperature (up to 30°C).